As exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential. Jenna Balestrini, head of strategy and business development at Draper, gives us her views on the biggest barriers to wider usage of these innovative treatments and how to overcome them.
Is CAR-T living up to its promise yet?
The promise of CAR-T is that we can have a single-dose curative solution to treat cancer, and in some ways that is true. There are some cases where a patient (such as Emily Whitehead) was dosed with an autologously-sourced cellular therapy after traditional approaches of radiation and chemo failed, and that cell therapy eradicated cancer in their body.
In that way CAR-T has and is living up to its promise as a curative solution. However, this is not the case for the majority of patients who receive this therapeutic. There are a number of issues including relapse, lack of specificity, limited response, toxicity and side effects. Also, there is a general lack of patient access, especially outside of the indications already approved for the two available cell therapies (Yescarta and Kymriah). Unless a patient is lucky enough to get into a certain trial, under certain care, with a certain kind of cancer, and with a certain kind of genetic predisposition, CAR-T may not work for them.
What needs to be done to fulfill the promise of CAR-T are two things. As a scientific community, we need to think more critically about ways we can broaden the abilities of these biologic agentsthese living cell therapiesto treat not just the immediate hematologic blood cancers but also those patients who have gone through multiple rounds of chemotherapy and radiation, which can seriously damage their initial blood material.
We also need to make a system that is much more one-size-fits-all in terms of its capability of treating cancer. So, the starting material needs to be better, and the biology needs to be more specific. For example, in the case of solid tumors, you need to have a scenario where the cell-based therapy doesnt introduce rejection via either graft-versus-host or host-versus-graft disease. We need to have a scenario where if you have a patient population that doesnt have, say, enough healthy T-cells to begin with, or have enough healthy blood material to work with, we will have a source for that starting material.
What are the biggest remaining unmet needs for patients when it comes to CAR-T?
There are both scientific and business needs that must be understood for these therapies.
The unmet scientific need is understanding why some of these CAR T-cell therapies work and why some dont. As scientists, we need to understand why certain patients respond better, and why we have scenarios in which we can readily adapt these therapeutics for some kinds of cancer but not others. Finally, we need to be able to create biologics that are readily available so that patients can get them when they are initially sick and not after multiple rounds of other options, like chemotherapy and radiation.
There are a large number of studies that show once a patient completes one to two rounds or more of chemotherapy or radiation, their cells are unable to efficaciously be changed into a cell-based therapy. Getting a patients materials earlier would be beneficial. For example, the first time you, as a patient, are diagnosed with cancer, you could have your cells removed and made into a therapeutic, and that would give you a much greater chance for the therapy to be successful. It would also avoid the current situation where your starting material is damaged through rounds of chemotherapy.
In terms of unmet business needs, it is safe to say that these customised immunotherapies are on the brink of revolutionizing how we treat cancer. The commercially approved applications of CAR-T therapies are currently limited to treating just a few kinds of blood cancers, and even these indications require a patient to have undergone several other therapies unsuccessfully. The reality is that when we do develop therapies for larger patient indications, the current healthcare system cannot afford them. Consider the cost of treating 300,000 cancer patients a year, roughly half of those that die from their disease. At $373,000 per patient, the increased burden to the healthcare system would not be sustainable. This cost does not include other associated costs from providing the therapy to the patient hospitalisation, medical support, etc. The unmet need is having a means to manufacture therapeutics at high volume, in significantly less time (i.e. less than 3 days), and at significantly lower cost per therapy. Patient access to these potentially life-saving therapies will require that the costs do not significantly increase the burden on the established healthcare systems.
What are some other barriers to widespread adoption of CAR-T and accessibility for patients?
Other barriers center on patient access to the therapy. For instance, one barrier is how clinical trials are set up, which patient cohorts are chosen and therefore are the contingency that are approved for the therapy use, and ultimately what patients are allowed to have access to them.
Another barrier is the current approach to introducing CAR T-cell therapy only after other treatment options are exhausted. This is a big challenge because its not just about the patients starting material but its about how sick the patient is once they get to you. A patient may have gone through seven rounds of chemotherapy and radiation, and now they are compromised. If we can make CAR-T a front-line therapy, it would make it more accessible and affordable.
What makes CAR-T treatments so expensive? Are there any ways to reduce costs?
One of the reasons CAR-T treatments are so expensive is that the industry does not have an automated, systematic manufacturing process, and because of that, there is an over-reliance on using instrumentation and processes that have been borrowed from other therapies, like blood banking or stem cell transplantation. Most cell therapy manufacturing processes came out of academic institutions. In academia, your touch labor is typically grad students and therefore is inexpensive, while the touch labor in industry is trained professionals and comes at a much higher cost. The high degree of touch labor also contributes to a breakdown in therapy development and hinders its scalability. Tissue engineering, as a field, suffered broadly for these exact reasons.
What difficulties exist in manufacturing CAR-T therapies? How are they affecting access?
CAR T-cells are a promising therapy, but the current state of biomanufacturing is very complex, expensive and time-consuming, often requiring multiple rooms, highly skilled technicians and many instruments. The process for developing CAR T-cell therapies involves gathering T cells from the cancer patients blood, re-engineering them in a lab so they will recognise cancer cells as an enemy and then reintroducing these enriched T cells to the patients body. The current price tag for a single treatment is $450,000. The typical timeframe is 12-17 days.
One reason for this bioprocessing bottleneck is that manufacturers are using equipment thats been retrofitted from other purposes, and then strung them together. With each step in the process, manufacturers typically have to conduct extra quality control measures, which can result in lost time and material and significant expense.
Whats needed is a bioprocessing platform that can help cell therapy developers bring their therapies to market more quickly, safely and affordably.
Draper is working to develop microfluidic platforms that will perform key steps of the CAR T-cell manufacturing process, as well as processes for other types of cell therapies. Innovations include a technique known as acoustophoresis for separating and enriching the immune system cell population that includes T cells using sound energy, as well as a platform for accelerating the process for transferring genetic material into T cells from the current one-to-three days to less than a day.
The goal of these microfluidic technologies is to create improvements in the cell therapy manufacturing process by combining fluidic control, precision and the ability to scale to higher throughput systems for easy integration with existing manufacturing equipment.
What are your future plans for the technology?
I can imagine a scenario where Draper is not just making devices that manufacture cell-based therapies but going further by incorporating artificial intelligence (e.g., machine learning) into these devices. This intelligence would enable us to not just study and learn from the data that is being extracted from our devices but also inform the process. I think thats the future of really smart engineering.
Read the rest here:
Q&A: Draper's Jenna Balestrini on the future of CAR-T - - pharmaphorum
- Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune - December 14th, 2019
- Acute Leukemia: 5 Things to Know - Medscape - December 14th, 2019
- Global T-Cell Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes) Market Size, Share & Trends Analysis Report 2019-2026 - ResearchAndMarkets.com... - December 14th, 2019
- CAMPUS: EGG DONATION - Artificial sperm cells to remove the genetic worries of sperm donation - ESHRE - December 14th, 2019
- Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2045 2017 - 2025 - Markets Gazette 24 - December 14th, 2019
- Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy - December 13th, 2019
- LentiGlobin Gene Therapy Continues to Show Promising Results in SCD, Updated Trial Data Shows - Sickle Cell Anemia News - December 13th, 2019
- CHMP Issues Positive Opinion Recommending DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple... - December 13th, 2019
- Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma - Hematology Advisor - December 13th, 2019
- Researchers ID Molecule that Appears to Halt and Reverse Scarring in Fibrotic Diseases - BioSpace - December 13th, 2019
- Canine Stem Cell Therapy Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 - Tech Estate Today - December 13th, 2019
- StemGenex - Stem Cell Therapy, Stem Cell Treatments, Stem ... - December 11th, 2019
- Cutting Edge Exosome Regenerative Therapy Comes to Yelm's AM Medical - ThurstonTalk - December 11th, 2019
- Sickle Cell Disease: Ex Vivo Cell Therapy Shines in Early Study - MedPage Today - December 11th, 2019
- Five recent drug target discoveries for pancreatic cancer - Drug Target Review - December 11th, 2019
- Immunotherapy drug improves outcomes for some children with relapsed leukemia - National Institutes of Health - December 11th, 2019
- 20(R)-Ginsenoside Rg3 Influences Cancer Stem Cell Properties and the E | OTT - Dove Medical Press - December 11th, 2019
- Patients closer to receiving regenerated tissue, scientists say - The Irish News - December 11th, 2019
- The Knesset dissolves and the public suffers - Ynetnews - December 11th, 2019
- Global T-Cell Therapy Market: Trends, Opportunities and Forecasts (2019-2026) - Therapy for Solid Tumors Expected to Emerge as a Lucrative Source of... - December 11th, 2019
- Layoffs at Fla.-based stem cell clinic accused of aggressively marketing patients - ABC Action News - December 11th, 2019
- Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells - BioSpace - December 11th, 2019
- New Mechanism of Bone Maintenance and Repair Discovered - Technology Networks - December 11th, 2019
- BMS' oral maintenance therapy boosts survival in AML patients - PMLiVE - December 11th, 2019
- Autoimmune Technologies Announces New Subsidiary to Develop Novel Antibody and Allogeneic Somatic Stem Cell Therapeutics For the Treatment of Invasive... - December 10th, 2019
- Microbial Dynamics in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation - Oncology Nurse Advisor - December 10th, 2019
- CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients... - December 10th, 2019
- Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual... - December 10th, 2019
- Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug... - December 10th, 2019
- Novartis sets 2020 target for commercial readiness of cell therapy CMO - BioPharma-Reporter.com - December 10th, 2019
- Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections - P&T Community - December 10th, 2019
- Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019... - December 10th, 2019
- ASH 2019: Second-gen CAR T-Cell Therapy Overcome Resistance, Reduce Toxicity and Simplify Treatment - OncoZine - December 10th, 2019
- IFN-: The T cell's license to kill stem cells in the inflamed intestine - Science - December 8th, 2019
- Movies opening in L.A. this week: 'Bombshell,' 'Jumanji: The Next Level' and more - Los Angeles Times - December 8th, 2019
- Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of... - December 8th, 2019
- Stem Cell Alopecia Treatment Market 2019 Business Growth, Size and Comprehensive Research Study Forecast to 2026 - Montana Ledger - December 8th, 2019
- Jasper Therapeutics launches out of Stanford with new approach to stem cell treatment - Endpoints News - December 7th, 2019
- MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute... - December 7th, 2019
- Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers - GlobeNewswire - December 7th, 2019
- Sickle Cell Anemia Patient Becomes First Person in the US to Have Her Genes Edited With CRISPR - Interesting Engineering - December 7th, 2019
- Teen diagnosed with cancer again just months after being told he beat disease - Mirror Online - December 7th, 2019
- Living with cancer: 'Exercising during my chemotherapy treatment worked wonders' - inews - December 7th, 2019
- Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis - Business Wire - December 7th, 2019
- Stem cells may trigger immune repair to mend hearts - BioNews - December 5th, 2019
- Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic... - December 5th, 2019
- Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment, By Region And Segment Forecasts, 2019 - 2026 - P&T Community - December 5th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is on Course to Expand at a CAGR of XX% Over the Forecast Period 2018 - 2026 - Weekly Spy - December 5th, 2019
- miR-194 Inhibits the Proliferation of SW620 Colon Cancer Stem Cells Th | CMAR - Dove Medical Press - December 5th, 2019
- Stem Cell Therapy Market Growth opportunities, Trends, Industry Analysis, and Forecast to 2020 - Kentucky Reports - December 5th, 2019
- As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types... - December 5th, 2019
- Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 - 2025 - The Market Expedition - December 5th, 2019
- Newly approved sickle cell drug ushers in an era of therapeutic breakthroughs - Worcester Telegram - December 5th, 2019
- A new stem cell therapy promises to heal injured heart - TheHealthSite - December 5th, 2019
- Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks - November 30th, 2019
- Phase 2 Trial Data on ALS NurOwn Therapy, Supporting Safety And Early Efficacy, Published - ALS News Today - November 30th, 2019
- Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential - Cancer Network - November 29th, 2019
- Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun - November 29th, 2019
- Mesenchymal Stem Cells Market Key Trends, Key Players, Challenges And Standardization, Analysis Of Key Players, And Forecast To 2026 - WindStreetz - November 29th, 2019
- Bone Therapeutics SA: Information on the total number of voting rights and shares - GlobeNewswire - November 29th, 2019
- Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Cancer Therapy Advisor - November 28th, 2019
- Why Stem Cell Therapy Might Be Your Answer To Chronic Pain - Patch.com - November 28th, 2019
- North-east toddler overcomes cancer after pioneering stem cell treatment - Press and Journal - November 28th, 2019
- Revolutionary stem cell banking and therapy from Celltex gives patients hope - KHOU.com - November 28th, 2019
- Kyoto University seeks approval to use stem cells in treatment for damaged knees - The Japan Times - November 28th, 2019
- Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy - Science Advances - November 28th, 2019
- Sickle Cell Disease: Current Treatment and Emerging Therapies - AJMC.com Managed Markets Network - November 28th, 2019
- Vertex plans major Boston expansion to support gene, cell therapy ambitions - FiercePharma - November 28th, 2019
- Discovery of 'Tendon Stem Cells' Could Revolutionize How We Recover From Injuries - Good News Network - November 28th, 2019
- You can take my Dads tweets over my dead body - TechCrunch - November 28th, 2019
- From Tiger Woods to Brooks Koepka, the 9 things we learned this fall on PGA Tour - Golf Channel - November 28th, 2019
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Future Growth, Industry Verticals, and Research Forecast upto 2026 - The Denton Chronicle - November 28th, 2019
- Stem Cell Therapy Market Gain Impetus due to the Growing Demand over 2025 - Guru Online News - November 28th, 2019
- Stem Cell Therapy Market Size, by Therapeutic Application (Musculoskeletal Disorders, Wounds and Injuries), by Cell Source (Adipose Tissue-derived... - November 28th, 2019
- Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Avon Lake Ledger - November 28th, 2019
- Translink in Armagh holding stem cell registration event in memory of Gavin McNaney - Armagh i - November 28th, 2019
- Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Hematology Advisor - November 25th, 2019
- Tendon stem cell discovery could lead to improvements in injury recovery - Drug Target Review - November 25th, 2019
- 2 Small-Cap Biotechs That Soared Last Week - Motley Fool - November 25th, 2019
- Cell Culture Market Size to Exceed US $42 Billion by 2026 - Post Register - November 25th, 2019